Key result
Review compares systemic, intracoronary, coronary sinus, and intramyocardial routes for cardiovascular cell-based therapy.
The field of myocardial regeneration utilizing novel cell-based therapies, gene transfer, and growth factors may prove to play an important role in the future management of ischemic heart disease and cardiomyopathy. Phases I and II clinical trials have been published for a variety of biologics utilizing four methods of delivery: systemic infusion, intracoronary infusion, transvenous coronary sinus, and intramyocardial. This review discusses the advantages and disadvantages of the delivery approaches above.
No takes yet. Share an insight, caveat, or question.
Dib et al. (2010) conducted a review in Ischemic heart disease and cardiomyopathy. Cell-based therapies (methods of delivery) was evaluated. A review of cell-based therapies for cardiovascular disease discusses the advantages and disadvantages of systemic, intracoronary, transvenous coronary sinus, and intramyocardial delivery methods.
Synapse has enriched 5 related papers. Consider them for comparative context: